Serious adverse events · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine changes serious adverse events compared with vandetanib (very low certainty).
1 finding from 1 review
Serious adverse events · episodic viral wheeze in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · episodic viral wheeze in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · School‐aged children and adults
Intermittent ICS showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Preschool children (<6 years)
Intermittent ICS showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · patients with anaemia
It is very uncertain whether parenteral iron changes serious adverse events compared with inactive control (very low certainty).
1 finding from 1 review
Serious adverse events · patients with anaemia
It is very uncertain whether parenteral iron changes serious adverse events compared with oral iron (very low certainty).
1 finding from 1 review
Serious adverse events · patients with anaemia
It is very uncertain whether oral iron changes serious adverse events compared with inactive control (very low certainty).
1 finding from 1 review
Serious adverse events · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT showed no clear difference in serious adverse events compared with CQ (high certainty).
1 finding from 1 review
Serious adverse events · patients with primary CNS lymphoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events · patients with rheumatoid arthritis pain
1 finding from 1 review
Serious adverse events · patients with Shigella dysentery
Cotrimoxazole led to lower serious adverse events compared with furazolidone; GRADE not reported.
1 finding from 1 review
Serious adverse events · patients with initial ART
TDF showed no clear difference in serious adverse events compared with AZT (high certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (SAEs) ‐ Network included 31 pairwise comparisons ‐ Mean risk with SUN across trials3 included in this network: 40.7% · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The intervention showed no clear difference in serious adverse events (SAEs) ‐ Network included 31 pairwise… (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events2,4 · Patients with advanced non‐small cell lung cancer
The intervention may leads to higher serious adverse events2,4 (low certainty).
1 finding from 1 review
RR 37.36 [10.66, 130.95]
1 study · 4 participants
Low
Serious adverse events Analysis 11.2 · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in serious adverse events Analysis 11.2 compared with methotrexate monotherapy (moderate certainty).
1 finding from 1 review
Adverse events ‐ Serious adverse events · people with inhibitors
Summary of findings table ‐ Concizumab prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (low certainty).
1 finding from 1 review
Adverse events ‐ Serious adverse events · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review